Pharmalive - The Pulse of the Pharmaceutical Industry
Search Criteria: Search In:  
Conferences


R&D Directions Insider

‘Milestone’ journey for anti-clotting agent

Thursday, July 16th, 2009

Since FDA’s decision to green light long-awaited blood thinner entry Effient was announced late last week, there has been much talk on the financial front over just how big a threat the Eli Lilly and Daiichi Sankyo Co. drug, which must carry a black box warning, will pose to longtime ...

Posted in Uncategorized, clinical trials | No Comments »

Prasugrel not pleasing

Wednesday, June 3rd, 2009

Since January 2008, FDA has been discussing the benefits over the risks of Eli Lilly’s prasugrel. The drug prevents more heart attacks than Plavix, but causes more internal bleeding, according to a study conducted by Lilly. Consumer health advocates and Dr. Victor Serebruany, who worked on the early development of ...

Posted in filed for approval | No Comments »

   
about us | advertise | contact us | home
terms of use | privacy | copyright | site map 		©2012 UBM Canon